Daewoong Pharm gains speed in global sales of Nabota beyond U.S.

[Photo by Daewoong Pharmaceutical Co.]

Daewoong Pharmaceutical Co. is speeding up penetration of its botulinum toxin supplies into global markets after resuming sales in the United States after settlement of dispute case.

The Korean pharmaceutical firm said on Thursday its botox product Nabota (known as Jeuveau in the U.S.) was recently cleared for marketing in Turkey and Chile and sales will officially begin in the third quarter of this year. The company is also working on a procedure to get marketing authorization in Columbia and other countries this year.

Daewoong Pharmaceutical is conducting a phase 3 trial to evaluate Nabota’s clinical benefits in square jaw reduction. The clinical trial is expected to be completed next year and marketing approval by Korea’s Ministry of Food and Drug Safety would follow, according to the company.

In Korea, Nabota is known to be effective in cosmetic indications such as improvement of glabellar lines and wrinkles around the eyes, and in the treatment of upper limb muscle stiffness and eyelid spasm after stroke.

Daewoong Pharmaceutical is accelerating efforts to sell Nabota as a treatment in the U.S. The company’s U.S. partner Evolus is selling Nabota for cosmetic purposes. AEON Biopharma, another U.S. firm, is seeking to sell Nabota for therapeutic purposes. AEON Biopharma is now conducting a phase 2 trial to evaluate Nabota’s efficacy and safety in prophylactic treatment.

Nabota sales came to a record 50.4 billion won ($44.6 million) last year since its Korean launch in 2014. Sales in the first quarter of this year reached 15.4 billion won, according to the company.

Daewoong Pharmaceutical’s shares rose 1.70 percent to 149,500 won as of 12:18 pm on Friday.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]